

## Savient Pharmaceuticals (SVNT) - Puricase: Market Assessment

Gauging clinical efficacy, treatment application, and reimbursement issues

### A survey among 50 Rheumatologists

#### Study Description

Methodology	Online survey
Data collection period	January 25-28, 2008
Survey audience	Rheumatologists (N = 50)

#### Study Objectives

Decision Metrics surveyed Rheumatologists to assess the market potential for Puricase within various sub-populations of gout patients. Specifically, we investigated four areas related to the potential level of acceptance and usage of Puricase among Rheumatologists.

- Understand market potential of Puricase:
  - Number and profile of gout patients who are suitable candidates for Puricase:
    - treatment-failure
    - persistent symptomatic
    - asymptomatic
- Gauge issues around a single course of therapy:
  - Expectations for how long the benefits of a single course of therapy are likely to last
  - Determination of minimum level of efficacy required for physicians to consider Puricase of “clinical relevance” and, therefore, recommend for treatment
- Investigate economics:
  - Assess patient criteria for evaluating patient suitability for infusion therapy
  - Explore physicians’ perspectives on patient criteria most likely to be used by managed care programs in deciding to reimburse infusion procedures

#### Companies and Products Mentioned in This Report

Company	Ticker Symbol	Product
Savient Pharmaceuticals, Inc.	SVNT	Puricase

**For additional information on this study or to purchase this report, please contact:**

Dan Meichenbaum

Phone: 415.263.6628; Email: dan.meichenbaum@wedbush.com